-       Report 
   - August 2024
    -  186 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                  -       Report 
   - July 2024
    -  150 Pages 
    Global
   
   From       €2692EUR$3,000USD£2,363GBP 
      €3365EUR$3,750USD£2,953GBP 
                -       Report 
   - September 2022
    -  120 Pages 
    Global
   
   From       €2243EUR$2,500USD£1,969GBP 
                -       Report 
   - April 2023
    -  240 Pages 
    Global
   
   From       €3230EUR$3,600USD£2,835GBP 
                -       Report 
   - April 2023
    -  82 Pages 
    North America
   
   From       €1346EUR$1,500USD£1,181GBP 
                 -       Report 
   - April 2023
    -  94 Pages 
    Africa, Middle East
   
   From       €1346EUR$1,500USD£1,181GBP 
                -       Report 
   - March 2023
    -  203 Pages 
    Global
   
   From       €3230EUR$3,600USD£2,835GBP 
                -       Report 
   - March 2023
    -  74 Pages 
    North America
   
   From       €1346EUR$1,500USD£1,181GBP 
                -       Report 
   - March 2023
    -  84 Pages 
    Middle East, Africa
   
   From       €1346EUR$1,500USD£1,181GBP 
                -       Report 
   - March 2023
    -  85 Pages 
    Europe
   
   From       €1346EUR$1,500USD£1,181GBP 
                -       Report 
   - March 2023
    -  84 Pages 
    Asia Pacific
   
   From       €1346EUR$1,500USD£1,181GBP 
                  -       Report 
   - January 2024
    -  150 Pages 
    Global
   
   From       €3455EUR$3,850USD£3,032GBP 
      €4352EUR$4,850USD£3,820GBP 
                  -       Report 
   - January 2024
    -  150 Pages 
    Global
   
   From       €3455EUR$3,850USD£3,032GBP 
      €4352EUR$4,850USD£3,820GBP 
                -       Report 
   - May 2024
    -  116 Pages 
    Global
   
   From       €3544EUR$3,950USD£3,111GBP 
                -       Report 
   - February 2024
    -  113 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - April 2023
    -  147 Pages 
    Global
   
   From       €4441EUR$4,949USD£3,898GBP 
                -       Report 
   - January 2024
    -  144 Pages 
    Global
   
   From       €3814EUR$4,250USD£3,347GBP 
                -       Report 
   - June 2025
    -  250 Pages 
    India
   
   From       €2503EUR$2,789USD£2,196GBP 
                -       Report 
   - May 2023
    -  140 Pages 
    Global
   
   From       €4441EUR$4,949USD£3,898GBP 
                  -       Report 
   - July 2024
    -  154 Pages 
    Global
   
   From       €3242EUR$3,613USD£2,845GBP 
      €3814EUR$4,250USD£3,347GBP 
             
         Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly    growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less   Read more